Senolytic drugs o-vanillin and RG-7112 successfully prevented pain behaviors and structural spine deterioration in sparc-deficient mice by clearing senescent cells from intervertebral discs, vertebral bone, and spinal cord tissue. The compounds reduced inflammatory markers while preserving disc volume and bone microarchitecture. This represents a significant advancement in preventive spine medicine, as back pain affects over 600 million people globally and current treatments primarily address symptoms rather than underlying cellular mechanisms. The senolytic approach directly targets a fundamental aging process—cellular senescence—that drives tissue inflammation and breakdown throughout the musculoskeletal system. While promising, translation to humans faces considerable hurdles. Mouse models don't fully replicate human spine biomechanics or pain complexity. The sparc-knockout model accelerates degeneration artificially, potentially making interventions appear more effective than they would be in natural aging. Safety profiles for chronic senolytic use remain unclear, particularly regarding effects on tissue repair and immune function. This proof-of-concept work is encouraging but requires human trials to determine whether preventive senolytic therapy could meaningfully reduce the epidemic of age-related spine problems.